Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1988 Aug;79(8):965–972. doi: 10.1111/j.1349-7006.1988.tb00062.x

Effect of Recombinant Human Interleukin 2 on the Growth of a BALB/c Sarcoma Induced by Moloney Murine Sarcoma Virus

Shin‐ichirou Mitsunaga 1,✉, Hideki Kimura 1, Yutaka Yamaguchi 1, Atsuo Mikata 2
PMCID: PMC5917605  PMID: 3141331

Abstract

The effect of in vivo administration of recombinant interleukin 2 (rIL2) on the growth of a primary female BALB/c sarcoma induced by Moloney marine sarcoma virus (M‐MSV) was studied. Although low‐dose administration of (6,000 JU/mouse × 14 days) rIL2 had no effect on the growth of the tumors, high‐dose (15,000–80,000 JU/mouse × 14 days) intraperitoneal inoculation of rIL2 induced tumor regression, dose‐dependently. Tumors in mice which received 80,000 JU/mouse/day of rIL2 regressed completely 2 weeks after the initiation of treatment. The survival rates of the treated groups were significantly higher than those of the control group. A time course experiment disclosed that the effect of rIL2 was restricted only to the group in which rIL2 treatment started 8 days after the inoculation of M‐MSV. The cytotoxic activity of regional lymph node lymphocytes from rIL2‐treated mice was demonstrated against primary culture of M‐MSV‐induced sarcoma but not against syngeneic tumor induced by methylcholanthrene (Meth A). The effect of rIL2 was partially blocked by the administration of anti‐IL2 receptor antibody. Immunohistochemical examination revealed that infiltration of Thy1.2+Lyt1+2‐ (helper/inducer subset) lymphocytes into the tumor tissue was prominent in mice which received high‐dose rIL2. The results indicated that IL2 induced regression of M‐MSV‐induced sarcoma mainly through activation of IL2‐receptor‐positive helper T cells in the tumor tissues and of killer cells in the draining lymph nodes.

Keywords: Interleukin 2, Tumor regression, Moloney murine sarcoma virus

Full Text

The Full Text of this article is available as a PDF (431.8 KB).

References

  • 1).Rosenberg , S. A. and Grim , E. A.Biological activity of recombinant human interleukin 2 produced in Escherichia coli . Science . 223 , 1412 – 1415 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 2).Rosenberg , S. A.Adoptive immunotherapy of cancer. Accomplishment and prospects . Cancer Treat. Rep. , 68 , 233 – 255 ( 1984. ). [PubMed] [Google Scholar]
  • 3).Mule , J. J. , Shu , S. , Schwarz , S. L. and Rosenberg , S. A.Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2 . Science , 225 , 1478 – 1489 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 4).Lotze , M. T. , Frana , L. W. , Sharrow , S. O. , Richard , J. R. and Rosenberg , S. A.In vivo administration of purified human interleukin 2 . J. Immunol. , 134 , 157 – 166 ( 1985. ). [PubMed] [Google Scholar]
  • 5).Rosenberg , S. A. , Mule , J. J. , Spiess , P. J. , Reichert , C. M. and Schwarz , S. L.Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high‐dose recombinant interleukin 2 . J. Exp. Med. , 161 , 1169 – 1188 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6).Mule , J. J. , Shu , S. and Rosenberg , S. A.The antitumor efficacy of lymphokine‐activated killer cells and recombinant interleukin 2 in vivo . J. Immunol. , 135 , 646 – 652 ( 1985. ). [PubMed] [Google Scholar]
  • 7).Lafreniere , R. and Rosenberg , S. A.Successful immunotherapy of murine experimental hepatic metastases with lymphokine‐activated killer cells and recombinant interleukin 2 . Cancer Res. , 45 , 3735 – 3741 ( 1985. ). [PubMed] [Google Scholar]
  • 8).Rayber , A. A. , Grimm , E. A. , Lotze , M. T. , Wilson , D. J. and Rosenberg , S. A.Lymphokine‐activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors . J. Natl. Cancer Inst. , 75 , 67 – 75 ( 1985. ). [PubMed] [Google Scholar]
  • 9).Lotze , M. T. , Robb , R. J. , Sharrow , S. O. , Frana , L. W. and Rosenberg , S. A.Systemic administration of interleukin 2 in man . J. Biol. Response Modif. , 3 , 475 – 481 ( 1984. ). [PubMed] [Google Scholar]
  • 10).Massicot , J. G. , Woods , W. A. and Chirigos , M. A.Cell line derived from a murine sarcoma virus (Moloney pseudo type)‐induced tumor: cultural, antigenic and virological properties . Appl. Microbiol. , 22 , 1119 – 1122 ( 1971. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11).Kimura , H. and Aoki , T.Enhancing and inhibiting effects of spleen cells from tumor‐bearing mice on growth of virus‐induced primary sarcoma . Br. J. Cancer , 37 , 553 – 565 ( 1978. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12).Kimura , H. , Yamaguchi , Y. and Fujisawa , T.Specific immunotherapy combined with whole body irradiation of BALB/c mice bearing Moloney murine sarcoma virus‐induced primary tumors . Gann , 73 , 446 – 453 ( 1982. ). [PubMed] [Google Scholar]
  • 13).Kimura , H. and Yamaguchi , Y.Distribution of in vitro‐stimulated immune lymphocytes in mice bearing Moloney murine sarcoma virus‐induced primary tumor . Gann , 72 , 72 – 80 ( 1981. ). [PubMed] [Google Scholar]
  • 14).Ettinghausen , S. E. , Lipford , E. H. , III , Mule , J. J. and Rosenberg , S. A.Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cells proliferation in tissues . J. Immunol. , 135 , 1488 – 1497 ( 1985. ). [PubMed] [Google Scholar]
  • 15).Ettinghausen , S. E. , Lipford , E. H. , III , Mule , J. J. and Rosenberg , S. A.Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine‐activated killer (LAK) cells . J. Immunol. , 135 , 3623 – 3635 ( 1985. ). [PubMed] [Google Scholar]
  • 16).Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Leitman , S. , Chang , A. E. , Ettinghausen , S. E. , Matory , Y. L. , Skibber , J. M. , Shiloni , E. , Vetto , J. T. , Seipp , C. A. , Simpson , C. and Reichert , C. M.Observations on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin 2 to patients with metastatic cancer . N. Engl. J. Med. , 313 , 1485 – 1492 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 17).Taniyama , T. and Holden , H. T.In vivo induction of T lymphocyte‐mediated cytotoxicity by infectious murine type c oncornaviruses . J. Exp. Med. , 150 , 1362 – 1382 ( 1979. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18).Plata , F. and Jongeneel , C. V.Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV)‐induced tumors . J. Immunol. , 119 , 623 – 629 ( 1977. ). [PubMed] [Google Scholar]
  • 19).Knight , R. A. and Gorczynski , R. M.Cell mediated immunity to Moloney sarcoma virus in mice. I. Analysis of antigens responsible for lymphocyte stimulation in regressor mice . Int. J. Cancer , 15 , 48 – 58 ( 1975. ). [DOI] [PubMed] [Google Scholar]
  • 20).Kirchner , H. , Glaser , M. , Holsen , H. T. and Heberman , R. B.Mixed lymphocyte‐tumor cell interaction in a murine sarcoma virus (Moloney)‐induced tumor system. Comparison between lymphoproliferation and lymphocyte cytotoxicity . Int. J. Cancer , 17 , 362 – 369 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 21).Forni , G. , Giovarelli , M. and Santoni , A.Lymphokine‐activated tumor inhibition in vivo . J. Immunol. , 134 , 1305 – 1311 ( 1985. ). [PubMed] [Google Scholar]
  • 22).Maekawa , R. , Matsumoto , M. , Kitagawa , T. , Harada , M. and Sato , K.Effect of recombinant interleukin 2 (R‐IL2) on the growth of murine myeloma X5563 . Cancer Immunol. Immunother. , 23 , 25 – 30 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23).Fujiwara , H. , Fukuzawa , M. , Yoshioka , T. , Nakajima , H. and Hamaoka , T.The role of tumor‐specific Lyt1+2− T cells in eradicating tumor cells in vivo . J. Immunol. , 133 , 1671 – 1676 ( 1984. ). [PubMed] [Google Scholar]
  • 24).Fujiwara , H. , Moriyama , Y. , Suda , T. , Tsuchida , T. , Shearer , G. M. and Hamaoka , T.Enhanced TNP‐reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression . J. Immunol. , 132 , 1571 – 1577 ( 1984. ). [PubMed] [Google Scholar]
  • 25).Greenberg , P. D. , Cheever , M. A. and Fefer , A.Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt1+2− lymphocytes . J. Exp. Med. , 154 , 952 – 963 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26).Gillis , S. and Smith , K. A.Long term culture of tumor‐specific cytotoxic T cells . Nature , 268 , 154 – 156 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 27).Rosenstein , M. , Yron , I. , Kaufmann , Y. and Rosenberg , S. A.Lymphokine‐activated killer cells: lysis of fresh syngeneic natural killer‐resistant murine tumor cells by lymphocytes cultured in interleukin 2 . Cancer Res. , 44 , 1946 – 1953 ( 1984. ). [PubMed] [Google Scholar]
  • 28).Rayer , A. A. , Grimm , E. A. , Lotze , M. T. , Chu , E. W. and Rosenberg , S. A.Lymphokine‐activated killer (LAK) cells . Cancer , 55 , 1327 – 1333 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 29).Mills , C. D. and North , R. J.Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient . J. Exp. Med. , 157 , 1448 – 1460 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES